Neovacs SA
3/5 Impasse Reille
Paris
75014
France
Tel: 33-0-153109300
Fax: 33-0-153109303
Website: http://www.neovacs.com/
Email: contact@neovacs.com
105 articles about Neovacs SA
-
Pharnext Announces that Neovacs Has Set Up a Management Trust to Manage the Pharnext Securities Issued and the Rights and Obligations of Neovacs under the Financing Agreement Signed on September 30th
10/31/2022
Pharnext SA announces the conclusion of an agreement with Neovacs for the establishment by Neovacs of a management trust, with Equitis Gestion as trustee, to exercise all of the rights and satisfy all of the obligations of the latter as well as manage the Pharnext securities issued by Pharnext respectively to Neovacs and the Trust, respectively, under the OBSA Agreement signed on September 30th, 2022 between Pharnext and Neovacs.
-
AstraZeneca and MedImmune announced top-line results from its TULIP 1 Phase III clinical trial of anifrolumab in adults with moderate-to-severe systemic lupus erythematosus (SLE). Unfortunately, the drug didn’t meet the trials primary endpoint of statistically-significant reduction in disease act...
-
Neovacs Announces Positive Data Review from Last IDSMB Review Prior to Final Results of Phase IIb Clinical Trial of IFNalpha Kinoid in Lupus
2/13/2018
This was the last IDSMB data review prior to the final results from this trial.
-
Neovacs: Strengthened Its Intellectual Property in Russia
1/16/2018
This patent covers IFNalpha kinoid and its application in all diseases related to an overproduction of IFNalpha cytokine.
-
Neovacs Announces Positive Results Of Preclinical Study for Ifnalpha Kinoidi in Type 1 Diabetes
12/12/2017
The ongoing PoC preclinical studies in Type 1 Diabetes in non-obese diabetic mice[1], conducted in collaboration with Dr. Agnès Lehuen and Pr. Christian Boitard, from the department of Immunology of Diabetes at the Hospital Cochin in Paris.
-
Neovacs Provides Business Update and Announces Half-Year 2017 Financial Results
10/27/2017
The company announced its financial results for the six-months ended June 30, 2017, as approved by the Company's Board of Directors on October 27, 2017.
-
Neovacs : Successfully Raises €6.0 Million In Private Placement With U.S. Biotechnology Institutional Investors
7/31/2017
-
Neovacs Announces FDA Acceptance Of A New IND To Expand In U.S. Ifnalpha Kinoid Clinical Development Program In Dermatomyositis
7/19/2017
-
Neovacs Announces License Agreement For IFNalpha Kinoid For Treatment Of Lupus In Turkey
7/5/2017
-
Neovacs Announces The Completion Of Patient Enrollment In Phase IIb Clinical Study Of IFNalpha Kinoid In Lupus
6/20/2017
-
Neovacs And Lupus Europe Join Voices On World Lupus Day
5/10/2017
-
Neovacs To Present Clinical Development Update On IFNa Kinoid in Dermatomyositis
5/4/2017
-
Week In Review: BioSense Signs $68 Million China Deal With Neovacs For Therapeutic Vaccine
2/27/2017
-
Neovacs 2017 Financial Calendar
2/7/2017
-
Neovacs Obtains FDA “Fast Track” Designation For IFNa Kinoid In Lupus (SLE)
12/7/2016
-
Neovacs Signs Production Partnership With 3P Biopharmaceuticals, A Leading GMP Producer Of Biological Drugs
11/28/2016
-
Neovacs Acquires Interferon Alpha Manufacturing Technology From AMEGABIOTECH
11/15/2016
-
Neovacs Enrolls The First U.S. Patient In Phase IIb Study Of Ifna Kinoid For Treatment Of Systemic Lupus Erythematosus (SLE)
11/7/2016
-
Neovacs Signs A Cooperation Agreement With The Department Immunology Of Diabetes At The Reputed Hospital Cochin In Paris
10/13/2016
-
Neovacs Signs A Cooperation Agreement With The Department Immunology Of Diabetes At The Reputed Hospital Cochin In Paris
10/13/2016